TTR and amyloidosis: Although the U.S. Food and Drug Administration (FDA) has indicated that the New Drug Application (NDA) for Tafamidis® has not yet been approved28, it has received approval for treatment of TTR amyloidosis in Europe, and has been used to treat TTR-FAP in Mexico, Japan, and Argentina29.